Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- bortezomib
- Duzallo (allopurinol / lesinurad)
Interactions between your drugs
bortezomib lesinurad
Applies to: bortezomib, Duzallo (allopurinol / lesinurad)
Information for this minor interaction is available on the professional version.
Drug and food interactions
allopurinol food
Applies to: Duzallo (allopurinol / lesinurad)
Allopurinol should generally be taken after a meal to reduce side effects. If your daily dose exceeds 300 mg, you may also ask your healthcare provider if it is okay to divide the total daily dose into smaller doses given more frequently instead of once a day, as this may also reduce stomach upset that can happen with allopurinol. It is best to avoid or limit the consumption of alcohol, as it can increase drowsiness or other nervous system side effects of allopurinol. You should also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
bortezomib food
Applies to: bortezomib
Limited evidence suggest that green tea may interfere with the antitumor effects of bortezomib. Until more information is available, it may be best to avoid or limit the consumption of green tea and green tea products during treatment with bortezomib. Talk to your doctor or pharmacist if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Velcade
Velcade injection is used to treat multiple myeloma and mantle cell lymphoma. Includes Velcade side ...
Gazyva
Gazyva is used to treat chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) in adults ...
Treanda
Treanda (bendamustine) is used to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is used for the treatment of relapsed or refractory multiple ...
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Jaypirca
Jaypirca (pirtobrutinib) is a cancer medicine used to treat types of CLL, SLL, and MCL. Includes ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.